News about Biotechnology

Biologos Appoints Hetal Patel as Chief Executive Officer

Biologos Appoints Hetal Patel as Chief Executive Officer

Biologos, a leading ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, announced the appointment of Hetal Patel as chief executive officer.

Biotechnology | 07/03/2026 | By Darshana 117

Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy

Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy

Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.

Biotechnology | 06/03/2026 | By News Bureau 143

South Africa pushes for local manufacturing of Gilead's HIV prevention drug

South Africa pushes for local manufacturing of Gilead's HIV prevention drug

Gilead Sciences’ long-acting HIV prevention drug, lenacapavir, could soon be produced in South Africa as the government pushes to expand regional manufacturing and improve access to the therapy.

Biotechnology | 05/03/2026 | By Darshana 105

YD Bio USA to Serve as Exclusive US Agent for YC Biotech's FDA Submissions

YD Bio USA to Serve as Exclusive US Agent for YC Biotech's FDA Submissions

YD Bio Limited has announced that its subsidiary, YD Bio USA, Inc., has entered into a master strategic alliance agreement with YC Biotech Co Ltd to establish a cross-border regulatory platform focused on US Food and Drug Administration (FDA) submissions.

Biotechnology | 01/03/2026 | By Darshana 120

GSK's Linerixibat Granted Priority Review in China for Cholestatic Pruritus in PBC

GSK's Linerixibat Granted Priority Review in China for Cholestatic Pruritus in PBC

China’s drug regulator has accepted GSK’s linerixibat for priority review to treat cholestatic pruritus in primary biliary cholangitis, supported by Phase III data showing significant and sustained itch relief.

Biotechnology | 27/02/2026 | By News Bureau 136

Novo Nordisk Signs USD 2.1 Billion Pact with Vivtex to Develop Oral Obesity Therapies

Novo Nordisk Signs USD 2.1 Billion Pact with Vivtex to Develop Oral Obesity Therapies

Novo Nordisk has entered into a strategic collaboration with US-based Vivtex to develop next-generation oral biologic therapies for obesity, diabetes and related metabolic conditions.

Biotechnology | 27/02/2026 | By Darshana 115

AS76 Brings Edge AI to Diagnostic Microscopy with On-Device High-Throughput Analysis

AS76 Brings Edge AI to Diagnostic Microscopy with On-Device High-Throughput Analysis

SigTuple has launched AS76, an AI-enabled digital morphology analyser designed to automate peripheral blood smear (PBS) microscopic review. The system integrates automated digital microscopy with on-device edge AI computing to deliver faster, standardized results while maintaining strict data privacy.

Biotechnology | 26/02/2026 | By Darshana 101

IBA and Shreeji Sign Multi-Site Deal to Deploy Four Cyclotrons Across India

IBA and Shreeji Sign Multi-Site Deal to Deploy Four Cyclotrons Across India

Ion Beam Applications S.A. (IBA), a global leader in particle accelerator technology and nuclear medicine solutions, has signed a multi-site agreement with Shreeji Imaging and Diagnostic Centre Pvt. Ltd. for the delivery and installation of four Cyclone KIUBE 300 cyclotrons in India.

Biotechnology | 21/02/2026 | By Darshana 176

Newron Strengthens Clinical Development Funding with Multi-Tranche Share Deal

Newron Strengthens Clinical Development Funding with Multi-Tranche Share Deal

Newron Pharmaceuticals has secured a staged equity financing agreement worth up to EUR 38 million from a consortium of existing and new investors in Europe and Asia, strengthening its balance sheet as it advances late-stage clinical development of evenamide for treatment-resistant schizophrenia.

Biotechnology | 18/02/2026 | By Darshana 131

Bio-Techne Corporation secures EU certification for Ella platform, expanding clinical diagnostic capabilities

Bio-Techne Corporation secures EU certification for Ella platform, expanding clinical diagnostic capabilities

Bio-Techne Corporation has received CE-IVD marking for its Ella benchtop immunoassay platform, enabling commercial availability across the European Union and opening new opportunities for clinical diagnostic use.

Biotechnology | 17/02/2026 | By Darshana 124

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members